Eli Lilly and Co. and Boehringer Ingelheim entered a global agreement to jointly develop and commercialize a portfolio of diabetes compounds currently in mid- and late-stage development. The portfolio includes Boehringer’s two oral diabetes agents, linagliptin and BI10773, and Lilly’s two basal insulin analogues, LY2605541 and LY2963016, with the option to co-develop and commercialize Lilly’s anti-TGF-beta monoclonal antibody. Linagliptin is being developed as an oral once-d...